DivestmentJul 23, 2026, 08:46 AM
Canton Strategic Holdings Sells Gravitas Life Sciences for $3.5M Note
AI Summary
Canton Strategic Holdings, Inc. has completed the sale of its wholly-owned clinical-stage biotech subsidiary, Gravitas Life Sciences, LLC, to Gravitas Collective Corp. The transaction, which closed on July 17, 2026, involved an unsecured promissory note of $3,500,000 and potential development milestone payments. This strategic divestment allows Canton Strategic Holdings to focus on its Canton Network strategy for the digitization of financial markets.
Key Highlights
- Canton Strategic Holdings sold its wholly-owned subsidiary, Gravitas Life Sciences, LLC.
- Consideration includes an unsecured promissory note for $3,500,000.
- The promissory note bears interest at 15% per annum, compounding semi-annually.
- Note maturity date is July 17, 2029, with mandatory and optional prepayment mechanisms.
- Company may receive additional development milestone payments from Gravitas Collective Corp.
- Certain bispecific antibodies development assets were retained by Canton's subsidiary, Tharimmune SPV1.
- Transaction was approved by a special committee of independent directors.
- Divestment aims to drive greater focus on the company's Canton Network strategy.
Price Impact
More from CNTN